Prostate Cancer

The top 5 OncLive TV videos of the week cover insights in lung cancer, and prostate cancer, myelofibrosis.

David Olmos, MD, PhD, discusses the evaluation of homologous recombination repair alterations in metastatic hormone-sensitive prostate cancer.

Phillip Koo, MD, discusses findings from a survey of prostate cancer screening rates.

Paul Gellhaus, MD, discusses ongoing developments with focal therapy in prostate cancer and potential avenues for technological improvement.

The FDA approved Enoby and Xtrenbo, denosumab biosimilars referencing Prolia and Xgeva, respectively.

Matthew R. Smith, MD, PhD, discussed patient characteristics and disease factors that influence treatment intensification decisions in mHSPC.

Paul Gellhaus, MD, spotlights key technological advancements and the need for consensus on PSA screening guidance during prostate cancer awareness month.

Vote in OncLive's polls to share which lung and genitournary cancer abstracts you're most anticipating at the 2025 ESMO Congress.

Two denosumab biosimilars received approval from the FDA for the purpose of increasing bone mass in individuals at high risk for fracture.

Alicia Morgans, MD, MPH, shares her typical work week, the importance of saying yes to career opportunities, and the value of trusted team communication.

Dana E. Rathkopf, MD, discusses the purpose of evaluating niraparib plus abiraterone acetate in metastatic castration-sensitive prostate cancer.

David Taub, MD, FACS, discusses how multidisciplinary care can optimize therapy selection for patients across different stages of prostate cancer.

FDA grants type A meeting to discuss RP1 BLA in melanoma, CBP/p300 bromodomain inhibitor gets fast track status in NSCLC, and more.

Rana R. McKay, MD, discusses unmet needs in mCRPC that led to the inception of the COMRADE trial.

Paul Gellhaus, MD, discusses the clinical implications of prostate cancer screening in recognition of Prostate Cancer Awareness Month.

David Olmos, MD, PhD, discusses the implications of data from the CAPTURE study for risk stratification in mHSPC harboring BRCA mutations.

Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.

The top 5 OncLive videos of the week cover insights in lung cancer, ovarian cancer, breast cancer, and prostate cancer.

The FDA has cleared a 3-month subcutaneous depot formulation of leuprolide mesylate in prostate cancer, gedatolisib NDA is under review in breast cancer, and more.

The FDA has approved a 3-month version of leuprolide mesylate for patients with advanced prostate cancer.

David Olmos, MD, PhD, discusses how data on the incidence of HRR alterations in metastatic prostate cancer can inform future research.

David Olmos, MD, PhD, discusses CAPTURE study findings on the prevalence of HRR mutations in mHSPC, highlighting prognostic impact and outcomes.

Health Canada has granted marketing authorization to darolutamide for the treatment of adult patients with metastatic castration-sensitive prostate cancer.

Matthew R. Smith, MD, PhD, discusses how PARP inhibition and radioligand therapies are shaping treatment decisions in advanced prostate cancer.